Neues #Antibiotikum könnte beim Kampf gegen #Antibiotikaresistenzen helfen: #Gepotidacin gegen Gonorrhö in Phase-3-Studie in The Lancet wirksam. Forschend betonten Relevanz neuer Wirkstoffe bei #Tripper, Pharmafirma strebt Zulassung auch in Europa an: https://www.sciencemediacenter.de/angebote/neuartiges-antibiotikum-gegen-gonorrhoe-25071/?mtm_campaign=mastodon&mtm_kwd=neuartiges-antibiotikum-gegen-gonorrhoe-25071
Recent searches
No recent searches
Search options
Only available when logged in.
eupolicy.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
This Mastodon server is a friendly and respectful discussion space for people working in areas related to EU policy. When you request to create an account, please tell us something about you.
Administered by:
Server stats:
244active users
eupolicy.social: About · Profiles directory · Privacy policy
Mastodon: About · Get the app · Keyboard shortcuts · View source code · v4.3.6
#gepotidacin
0 posts · 0 participants · 0 posts today
ExploreLive feeds
Mastodon is the best way to keep up with what's happening.
Follow anyone across the fediverse and see it all in chronological order. No algorithms, ads, or clickbait in sight.
Create accountLoginDrag & drop to upload